Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy
暂无分享,去创建一个
J. Zak | D. Weisdorf | U. Farooq | V. Bachanova | M. Janakiram | Q. Cao | V. Kenkre | L. Hegerova | S. Ayyappan | J. Maakaron